case_images: PMC4238166_01
case_images: HSRT treatment plan: the axial (a), sagittal (b), coronal (c), and three-dimensional view (d). Red line: 100% isodose line; Yellow line: 95% isodose line; green line: 80% isodose line.
case_images: CRIHEP2013-146215.001.jpg
case_images: PMC4238166_01_CRIHEP2013-146215.001.jpg
case_images: fig1
case_images: According to our internal protocol based on the recent literature data (5), HSRT was delivered in 5 fractions for a total of 40 Gy on alternate days, and dose was prescribed to the 97% isodose line (Figure 1).
case_images: Changes in alpha-FP levels after HSRT.
case_images: CRIHEP2013-146215.002.jpg
case_images: PMC4238166_01_CRIHEP2013-146215.002.jpg
case_images: fig2
case_images: At 1, 2, and 3 months after HSRT, ALP, GGT, and a-FP decreased, respectively, to 411  400 361 U/L, 199 156 118 U/L, and 107,6  38 19,8 ng/mL; a further reduction of a-FP value at 7,4 ng/mL was observed within 6 months (Figure 2).
case_images: Abdominal computed tomography scans before and 6 months after HSRT show a complete disappearance of hypervascular arterial enhancement of primary tumour.
case_images: CRIHEP2013-146215.003.jpg
case_images: PMC4238166_01_CRIHEP2013-146215.003.jpg
case_images: fig3
case_images: CT scan showed a 90% objective tumour response and a complete remission at 3 and 6 months after treatment, respectively (Figure 3). 